NGM BIOPHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $4.4M | $55.3M | $77.9M | $87.4M | $103.5M | $108.7M |
| Operating income | −$151.5M | −$166.2M | −$120.7M | −$103.8M | −$49.3M | −$4.3M |
| Net income | −$142.4M | −$162.7M | −$120.3M | −$102.5M | −$42.8M | −$493,000 |
| Total assets | $168.9M | $307.4M | $402.4M | $329.0M | $380.4M | $246.1M |
| Total liabilities | $20.2M | $47.8M | $66.7M | $49.0M | $49.7M | $59.4M |
| Equity | $148.6M | $259.6M | $335.6M | $280.0M | $330.7M | −$108.2M |
| EPS (diluted) | $-1.73 | $-2.03 | $-1.56 | $-1.50 | $-0.85 | — |
| Shares out. | 82.0M | 78.0M | 76.7M | 67.8M | 67.0M | 6.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −3429.1%
- Net margin
- −3223.3%
- Return on equity
- −95.8%
- Return on assets
- −84.3%
- Return on capital (ROCE)
- −101.8%
- Liabilities / assets
- 12.0%
- Debt / equity
- 0.14×
- Book value / share
- $1.81
- Revenue growth (YoY)
- −92.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -6.99distress
- Accruals / assets
- −6.0%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2025-02Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Phase 1Active Not Recruitingreadout ~2025-07Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Phase 2Recruitingreadout ~2027-04An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Tcg Opportunity Iii Gp, Llc10% owner | Apr 5, 2024 | D | 949,862 | — |
| Column Group Gp, Lp10% owner | Apr 5, 2024 | D | 949,862 | — |
| Column Group L PDirector | Apr 5, 2024 | D | 949,862 | — |
| Goeddel David VDirector | Apr 5, 2024 | D | 134,180 | — |
| Pierce Valerie LOfficer — See Remarks | Apr 5, 2024 | U | 26,458 | — |
| Rieflin William JlDirector | Apr 5, 2024 | U | 5,172 | — |
| Viret Jean-FredericOfficer — Chief Financial Officer | Apr 5, 2024 | U | 3,038 | — |
| Woodhouse David JOfficer — Chief Executive Officer | Apr 5, 2024 | U | 23,993 | — |
| Perlich IreneOfficer — Principal Accounting Officer | Apr 5, 2024 | U | 6,284 | — |
| Hooper Suzanne SawochkaDirector | Apr 5, 2024 | U | 7,000 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventApr 5, 2024
- Results of operationsMar 11, 2024
- Entered a material agreement · Regulation FD disclosureFeb 26, 2024
- Other material eventJan 22, 2024
- Other material eventJan 2, 2024
- Delisting / listing-standard noticeDec 4, 2023
- Results of operationsNov 2, 2023
- Director / officer changeOct 17, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GFORM 15-12GApr 15, 2024
- EFFECTApr 8, 2024
- 4OWNERSHIP DOCUMENTApr 8, 2024
- 4OWNERSHIP DOCUMENTApr 8, 2024
- 4OWNERSHIP DOCUMENTApr 8, 2024
- 4OWNERSHIP DOCUMENTApr 8, 2024
- 4Apr 8, 2024
- 4Apr 8, 2024
- 4Apr 8, 2024
- 4Apr 8, 2024
- 4Apr 8, 2024
- 4Apr 8, 2024
- 4Apr 8, 2024
- 4Apr 8, 2024
- 4Apr 8, 2024